The effect of bumetanide on schizophrenia patients
- Conditions
- schizopherenia.schizopherenia
- Registration Number
- IRCT2014012616374N1
- Lead Sponsor
- Vice chancellor for research, university of Social Welfare & Rehabilitation sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
inclusion criteria: (1) Diagnosis of schizophrenia at any subtype according to DSM-IV diagnosis an statistical manual of mental disorders, 4th edition (2) aged 20 to 70 years (3) disease duration for at least 3 years (4) had a total score of at least 70 on the positive and negative syndrome scale(PANSS) (5) had persistent negative or considerable cognitive symptoms, that are equivalent with at least 20 and 15 score on the negative and cognitive subscales of PANSS, respectively. Exclusion criteria were: patients with a (1) documented fluctuation in symptoms (2) uncontrollable significant conditions (3) As well as concurrent history of significant psychiatric (except schizophrenia), cardiovascular, renal, hepatic, convulsive disorders or substance abuse.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative, positive and cognitive symptoms of schizopherenic patients. Timepoint: Before treatment and 1, 2 months after treatment and following one-month drug-free washout period. Method of measurement: PANSS and BPRS inquiries.
- Secondary Outcome Measures
Name Time Method Side effect. Timepoint: at assessment interviews; before treatment and 1,2 months after treatment and after one-month drug-free washout period. Method of measurement: AIMS test and clinical observation.